

# Index

- Acosta, M. *see* Iglesias, P.  
 Agosti, B. *see* Cappelli, C.  
 Akalin, S. *see* Yavuz, D.  
 Akgul, E.O. *see* Ozcan, O.  
 Akre, O. *see* Berinder, K.  
 Alexiadis, M. *see* Fuller, P.J.  
 Allemann, S. *see* Trepp, R.  
 Al-Qahtani, A., Muttukrishna, S., Appasamy, M., Johns, J., Cranfield, M., Visser, J.A., Themmen, A.P.N. and Groome, N.P. Development of a sensitive enzyme immunoassay for anti-Müllerian hormone and the evaluation of potential clinical applications in males and females, 267  
 Ambrosio, M.R. *see* Tita, P.  
 Ammini, A.C. *see* Turton, J.P.G.  
 Andria, G. *see* Melis, D.  
 Appasamy, M. *see* Al-Qahtani, A.  
 Arwert, L.I., Roos, J.C., Lips, P., Twisk, J.W.R., Manoliu, R.A. and Drent, M.L. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men, 310  
 Asano, A. *see* Liang, H.  
 Atkinson, A.B., Kennedy, A., Wiggam, M.I., McCance, D.R. and Sheridan, B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance, 549  
 Auriemma, R.S. *see* Colao, A.  
 Auriemma, R.S. *see* Vitale, G.  
 Aversa, A. *see* Isidori, A.M.  
 Aydin, T., Karacan, I., Demir, S.E. and Sahin, Z. Bone loss in males with ankylosing spondylitis: its relation to sex hormone levels, 467  
 Baek, K.H. *see* Oh, K.W.  
 Bähr, V. *see* Mai, K.  
 Baik, S.H. *see* Kim, S.M.  
 Baldazzi, L. *see* Nicoletti, A.  
 Baldeschi, L. *see* Wakelkamp, I.M.M.J.  
 Balsamo, A. *see* Nicoletti, A.  
 Bana, N. *see* Brierley, J.  
 Barbaro, D., Simi, U., Meucci, G., Lapi, P., Orsini, P. and Pasquini, C. Thyroid papillary cancers: microcarcinoma and carcinoma, incidental cancers and non-incidental cancers – are they different diseases?, 577  
 Barbieri, M. *see* Rizzo, M.R.  
 Barp, L. *see* Nicoletti, A.  
 Barreca, A. *see* Resmini, E.  
 Barrett, P.H.R. *see* Ng, T.W.K.  
 Bartalena, L. *see* Bogazzi, F.  
 Baxter, R.C. *see* Nelson, A.E.  
 Beck-Peccoz, P. *see* Morpurgo, P.S.  
 Bellastella, A. *see* De Bellis, A.  
 Belloni, D.R. *see* Kinlaw, W.B.  
 Benigno, V. *see* Melis, D.  
 Berinder, K., Stackenäs, I., Akre, O., Hirschberg, A.L. and Hulting, A.-L. Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up, 450  
 Berlioli, M.G. *see* Celi, F.  
 Besser, G.M. *see* Chung, T.T.  
 Betterle, C. *see* De Bellis, A.  
 Beyhan, Z. *see* Ozcan, O.  
 Biber, F.Z. *see* Darcan, Ş.  
 Bilgi, C. *see* Ozcan, O.  
 Bindi, G. *see* Stagi, S.  
 Bini, V. *see* Celi, F.  
 Biswas, M., Smith, J., Jadon, D., McEwan, P., Rees, D.A., Evans, L.M., Scanlon, M.F. and Davies, J.S. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas, 26  
 Bizzarro, A. *see* De Bellis, A.  
 Bobbert, T. *see* Mai, K.  
 Bobbert, T., Brechtel, L., Mai, K., Otto, B., Maser-Gluth, C., Pfeiffer, A.F.H., Spranger, J. and Diederich, S. Adaptation of the hypothalamic-pituitary hormones during intensive endurance training, 530  
 Boerlin, V. *see* van der Hoek, J.  
 Bogazzi, F., Russo, D., Locci, M.T., Chifenti, B., Ultimieri, F., Raggi, F., Cosci, C., Sardella, C., Costa, A., Gasperi, M., Bartalena, L. and Martino, E. Apoptosis is reduced in the colonic mucosa of patients with acromegaly, 683  
 Bolund, L. *see* Siggaard, C.  
 Bona, G. *see* Camilot, M.  
 Bondanelli, M. *see* Tita, P.  
 Bonifacio, V. *see* Isidori, A.M.  
 Bouloux, P.M. *see* Turton, J.P.G.  
 Bowers, C.Y. *see* Soares-Welch, C.  
 Bravata, D.M. *see* Liu, H.  
 Brechtel, L. *see* Bobbert, T.  
 Bremner, A.P. *see* Walsh, J.P.  
 Brierley, J., Tsang, R., Panzarella, T. and Bana, N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years, 418  
 Briganti, F. *see* Colao, A.  
 Brismar, K. *see* Undén, A.-L.  
 Broch, M. *see* González-Clemente, J.M.  
 Broch, M. *see* Vilarrasa, N.  
 Bronstein, M., Musolino, N., Jallad, R., Cendros, J.M., Ramis, J., Obach, R., Leselbaum, A. and Catus, F. Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days, 514  
 Bronstein, M.D. *see* Jallad, R.S.  
 Bulsara, M.K. *see* Walsh, J.P.  
 Burlina, A.B. *see* Melis, D.  
 Cabaccan, J. *see* Liu, H.  
 Cacciari, E. *see* Nicoletti, A.  
 Caglières, C. *see* Canale, D.  
 Caixàs, A. *see* González-Clemente, J.M.

# Index

- Acosta, M. *see* Iglesias, P.  
 Agosti, B. *see* Cappelli, C.  
 Akalin, S. *see* Yavuz, D.  
 Akgul, E.O. *see* Ozcan, O.  
 Akre, O. *see* Berinder, K.  
 Alexiadis, M. *see* Fuller, P.J.  
 Allemann, S. *see* Trepp, R.  
 Al-Qahtani, A., Muttukrishna, S., Appasamy, M., Johns, J., Cranfield, M., Visser, J.A., Themmen, A.P.N. and Groome, N.P. Development of a sensitive enzyme immunoassay for anti-Müllerian hormone and the evaluation of potential clinical applications in males and females, 267  
 Ambrosio, M.R. *see* Tita, P.  
 Ammini, A.C. *see* Turton, J.P.G.  
 Andria, G. *see* Melis, D.  
 Appasamy, M. *see* Al-Qahtani, A.  
 Arwert, L.I., Roos, J.C., Lips, P., Twisk, J.W.R., Manoliu, R.A. and Drent, M.L. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men, 310  
 Asano, A. *see* Liang, H.  
 Atkinson, A.B., Kennedy, A., Wiggam, M.I., McCance, D.R. and Sheridan, B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance, 549  
 Auriemma, R.S. *see* Colao, A.  
 Auriemma, R.S. *see* Vitale, G.  
 Aversa, A. *see* Isidori, A.M.  
 Aydin, T., Karacan, I., Demir, S.E. and Sahin, Z. Bone loss in males with ankylosing spondylitis: its relation to sex hormone levels, 467  
 Baek, K.H. *see* Oh, K.W.  
 Bähr, V. *see* Mai, K.  
 Baik, S.H. *see* Kim, S.M.  
 Baldazzi, L. *see* Nicoletti, A.  
 Baldeschi, L. *see* Wakelkamp, I.M.M.J.  
 Balsamo, A. *see* Nicoletti, A.  
 Bana, N. *see* Brierley, J.  
 Barbaro, D., Simi, U., Meucci, G., Lapi, P., Orsini, P. and Pasquini, C. Thyroid papillary cancers: microcarcinoma and carcinoma, incidental cancers and non-incidental cancers – are they different diseases?, 577  
 Barbieri, M. *see* Rizzo, M.R.  
 Barp, L. *see* Nicoletti, A.  
 Barreca, A. *see* Resmini, E.  
 Barrett, P.H.R. *see* Ng, T.W.K.  
 Bartalena, L. *see* Bogazzi, F.  
 Baxter, R.C. *see* Nelson, A.E.  
 Beck-Peccoz, P. *see* Morpurgo, P.S.  
 Bellastella, A. *see* De Bellis, A.  
 Belloni, D.R. *see* Kinlaw, W.B.  
 Benigno, V. *see* Melis, D.  
 Berinder, K., Stackenäs, I., Akre, O., Hirschberg, A.L. and Hulting, A.-L. Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up, 450  
 Berlioli, M.G. *see* Celi, F.  
 Besser, G.M. *see* Chung, T.T.  
 Betterle, C. *see* De Bellis, A.  
 Beyhan, Z. *see* Ozcan, O.  
 Biber, F.Z. *see* Darcan, Ş.  
 Bilgi, C. *see* Ozcan, O.  
 Bindi, G. *see* Stagi, S.  
 Bini, V. *see* Celi, F.  
 Biswas, M., Smith, J., Jadon, D., McEwan, P., Rees, D.A., Evans, L.M., Scanlon, M.F. and Davies, J.S. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas, 26  
 Bizzarro, A. *see* De Bellis, A.  
 Bobbert, T. *see* Mai, K.  
 Bobbert, T., Brechtel, L., Mai, K., Otto, B., Maser-Gluth, C., Pfeiffer, A.F.H., Spranger, J. and Diederich, S. Adaptation of the hypothalamic-pituitary hormones during intensive endurance training, 530  
 Boerlin, V. *see* van der Hoek, J.  
 Bogazzi, F., Russo, D., Locci, M.T., Chifenti, B., Ultimieri, F., Raggi, F., Cosci, C., Sardella, C., Costa, A., Gasperi, M., Bartalena, L. and Martino, E. Apoptosis is reduced in the colonic mucosa of patients with acromegaly, 683  
 Bolund, L. *see* Siggaard, C.  
 Bona, G. *see* Camilot, M.  
 Bondanelli, M. *see* Tita, P.  
 Bonifacio, V. *see* Isidori, A.M.  
 Bouloux, P.M. *see* Turton, J.P.G.  
 Bowers, C.Y. *see* Soares-Welch, C.  
 Bravata, D.M. *see* Liu, H.  
 Brechtel, L. *see* Bobbert, T.  
 Bremner, A.P. *see* Walsh, J.P.  
 Brierley, J., Tsang, R., Panzarella, T. and Bana, N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years, 418  
 Briganti, F. *see* Colao, A.  
 Brismar, K. *see* Undén, A.-L.  
 Broch, M. *see* González-Clemente, J.M.  
 Broch, M. *see* Vilarrasa, N.  
 Bronstein, M., Musolino, N., Jallad, R., Cendros, J.M., Ramis, J., Obach, R., Leselbaum, A. and Catus, F. Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days, 514  
 Bronstein, M.D. *see* Jallad, R.S.  
 Bulsara, M.K. *see* Walsh, J.P.  
 Burlina, A.B. *see* Melis, D.  
 Cabaccan, J. *see* Liu, H.  
 Cacciari, E. *see* Nicoletti, A.  
 Caglièresi, C. *see* Canale, D.  
 Caixàs, A. *see* González-Clemente, J.M.

- Cakir, E. *see* Ozcan, O.
- Camilot, M., Teofoli, F., Gandini, A., Franceschi, R., Rapa, A., Corrias, A., Bona, G., Radetti, G. and Tatò, L. Thyrotropin receptor gene mutations and TSH resistance: variable expressivity in the heterozygotes, 146
- Canale, D., Caglieresi, C., Moschini, C., Liberati, C.D., Macchia, E., Pinchera, A. and Martino, E. Androgen receptor polymorphism (CAG repeats) and androgenicity, 356
- Capanna, R. *see* Mohn, A.
- Cappabianca, P. *see* Colao, A.
- Cappelli, C., Pirola, I., Cumetti, D., Micheletti, L., Tironi, A., Gandossi, E., De Martino, E., Cherubini, L., Agosti, B., Castellano, M., Mattanza, C. and Rosei, E.A. Is the anteroposterior and transverse diameter ratio of nonpalpable thyroid nodules a sonographic criteria for recommending fine-needle aspiration cytology?, 689
- Cappiello, V. *see* Morpurgo, P.S.
- Carta, A. *see* Tita, P.
- Casa, R.D. *see* Melis, D.
- Cassar, J. *see* Turton, J.P.G.
- Castellano, M. *see* Cappelli, C.
- Caterina, G. *see* Palomba, S.
- Catus, F. *see* Bronstein, M.
- Celi, F., Bini, V., Papi, F., Santilli, E., Ferretti, A., Mencacci, M., Berlioli, M.G., De Giorgi, G. and Falorni, A. Circulating acylated and total ghrelin and galanin in children with insulin-treated type 1 diabetes: relationship to insulin therapy, metabolic control and pubertal development, 139
- Cendros, J.M. *see* Bronstein, M.
- Chan, D.C.F. *see* Ng, T.W.K.
- Chan, I.H.S. *see* Ng, P.C.
- Channer, K.S. *see* Kapoor, D.
- Chen, Y.-J. *see* Liu, R.-T.
- Cheng, J.-T. *see* Liu, R.-T.
- Cherubini, L. *see* Cappelli, C.
- Chew, S.L. *see* Chung, T.T.
- Chiarelli, F. *see* Mohn, A.
- Chiarelli, F. *see* Stagi, S.
- Chifenti, B. *see* Bogazzi, F.
- Ching, H.L. *see* Ng, T.W.K.
- Cho, Y.M. *see* Kim, T.Y.
- Choi, D.S. *see* Kim, S.M.
- Choi, K.M. *see* Kim, S.M.
- Choi, M.G. *see* Oh, K.W.
- Chong, K. *see* Turton, J.P.G.
- Chou, F.-F. *see* Liu, R.-T.
- Christ, E.R. *see* Trepp, R.
- Christensen, J.H. *see* Siggaard, C.
- Christiansen, P. *see* Moosgaard, B.
- Chrousos, G.P. and Kaltsas, G. Post-SARS sickness syndrome manifestations and endocrinopathy: how, why, and so what?, 363
- Chung, T.T., Drake, W.M., Evanson, J., Walker, D., Plowman, P.N., Chew, S.L., Grossman, A.B., Besser, G.M. and Monson, J.P. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement, 274
- Chung, U.-I. *see* Lee, S.
- Cicognani, A. *see* Nicoletti, A.
- Cochran, E. *see* Musso, C.
- Coker, M. *see* Darcan, S.
- Colao, A. *see* Palomba, S.
- Colao, A. *see* Vitale, G.
- Colao, A., Pivonello, R., Cappabianca, P., Briganti, F., Tortora, F., Auremma, R.S., De Martino, M.C., Marzullo, P. and Lombardi, G. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly, 342
- Cole, D. *see* Soule, S.
- Cole, T.J. *see* Mehta, A.
- Conaglen, J.V. *see* Learoyd, D.L.
- Conte, M. *see* De Bellis, A.
- Copinschi, G. *see* Leproult, R.
- Coronella, C. *see* De Bellis, A.
- Corrias, A. *see* Camilot, M.
- Corydon, T.J. *see* Siggaard, C.
- Cosci, C. *see* Bogazzi, F.
- Costa, A. *see* Bogazzi, F.
- Cranfield, M. *see* Al-Qahtani, A.
- Crown, A. and Lightman, S. Why is the management of glucocorticoid deficiency still controversial: a review of the literature, 483
- Cumetti, D. *see* Cappelli, C.
- D'Andrea, F. *see* Rizzo, M.R.
- Daniels, G.H. *see* Kinlaw, W.B.
- Darcan, S., Unak, P., Yalman, O., Lambrecht, F.Y., Biber, F.Z., Göksen, D. and Coker, M. Determination of iodine concentration in urine by isotope dilution analysis and thyroid volume of school children in the west coast of Turkey after mandatory salt iodization, 543
- Dattani, M.T. *see* Mehta, A.
- Dattani, M.T. *see* Turton, J.P.G.
- Dattani, M.T. Growth hormone deficiency and combined pituitary hormone deficiency: does the genotype matter?, 121
- Davies, J.H., Evans, B.A.J., Jenney, M.E.M. and Gregory, J.W. Skeletal morbidity in childhood acute lymphoblastic leukaemia, 1
- Davies, J.S. *see* Biswas, M.
- De Bellis, A., Bizzarro, A., Perrino, S., Coronella, C., Conte, M., Pasquali, D., Sinisi, A.A., Betterle, C. and Bellastella, A. Characterization of antipituitary antibodies targeting pituitary hormone-secreting cells in idiopathic growth hormone deficiency and autoimmune endocrine diseases, 45
- De Giorgi, G. *see* Celi, F.
- De Martino, E. *see* Cappelli, C.
- De Martino, M.C. *see* Colao, A.
- Deeb, A., Mason, C., Lee, Y.S. and Hughes, I.A. Correlation between genotype, phenotype and sex of rearing in 111 patients with partial androgen insensitivity syndrome, 56
- Deeg, D.J.H. *see* Puts, M.T.E.
- Delbridge, L.W. *see* Learoyd, D.L.
- Demir, S.E. *see* Aydin, T.
- Di Marzio, D. *see* Mohn, A.
- Di Rocco, M. *see* Melis, D.
- Diederich, S. *see* Bobbert, T.
- Diederich, S. *see* Mai, K.
- Díez, J.J. *see* Iglesias, P.

- Donati, A. *see* Melis, D.  
 Doyle, M.E. *see* Hardin, D.S.  
 Drake, W.M. *see* Chung, T.T.  
 Drent, M.L. *see* Arwert, L.I.  
 Drop, S.L.S. *see* Mul, D.  
 Dudczak, R. *see* Karanikas, G.  
 Dunger, D.B. *see* Yuen, K.C.J.  
 Dwivedi, M. *see* Sinha, S.  
 Egle, U.T. *see* Kahaly, G.J.  
 Elofsson, S. *see* Undén, A.-L.  
 Elston, M.S. *see* Learoyd, D.L.  
 Engelmann, M.D. *see* Øgaard, C.G.  
 Erbil, M.K. *see* Ozcan, O.  
 Ernesti, M.M. *see* Kinlaw, W.B.  
 Erturk, K. *see* Ozcan, O.  
 Estepa, A. *see* Vilarrasa, N.  
 Eunice, M. *see* Turton, J.P.G.  
 Evans, B.A.J. *see* Davies, J.H.  
 Evans, L.M. *see* Biswas, M.  
 Evanson, J. *see* Chung, T.T.  
 Everts, R. *see* Trepp, R.  
 Fabbri, A. *see* Isidori, A.M.  
 Falbo, A. *see* Palomba, S.  
 Falorni, A. *see* Celi, F.  
 Feddema, P. *see* Walsh, J.P.  
 Feelders, R.A. *see* van der Hoek, J.  
 Feldt-Rasmussen, U. *see* Klose, M.  
 Fernández-Reyes, M.J. *see* Iglesias, P.  
 Ferone, D. *see* Resmini, E.  
 Ferraroni, N.R., Geloneze, B., Mansour, E., Perroud, A.P., Muscelli, E.O., Tambascia, M., de Lima Zollner, R. and Velloso, L.A. Severe hypoleptinaemia associated with insulin resistance in patients with common variable immunodeficiency, 63  
 Ferretti, A. *see* Celi, F.  
 Fischli, S. *see* Trepp, R.  
 Fok, T.F. *see* Ng, P.C.  
 Franceschi, R. *see* Camilot, M.  
 Fryklund, L. *see* Yuen, K.C.J.  
 Frystyk, J. *see* Yuen, K.C.J.  
 Fuller, P.J., Alexiadis, M., Jobling, T. and McNeillage, J. Seladin-1/DHCR24 expression in normal ovary, ovarian epithelial and granulosa tumours, 111  
 Furlan, F. *see* Melis, D.  
 Gómez, J.M. *see* Vilarrasa, N.  
 Göksen, D. *see* Darcan, Ş.  
 Gandini, A. *see* Camilot, M.  
 Gandossi, E. *see* Cappelli, C.  
 Gangemi, P. *see* Tita, P.  
 Gasperi, M. *see* Bogazzi, F.  
 Gatti, R. *see* Melis, D.  
 Geesey, M.E. *see* Hueston, W.J.  
 Geloneze, B. *see* Ferraroni, N.R.  
 Gennari, M. *see* Nicoletti, A.  
 Gianfrilli, D. *see* Isidori, A.M.  
 Giannetta, E. *see* Isidori, A.M.  
 Giannini, C. *see* Mohn, A.  
 Giménez-Pérez, G. *see* González-Clemente, J.M.  
 Giménez-Palop, O. *see* González-Clemente, J.M.  
 Giusti, M. *see* Resmini, E.  
 Gong, G. *see* Kim, T.Y.  
 González-Clemente, J.M., Mauricio, D., Richart, C., Broch, M., Caixàs, A., Megia, A., Giménez-Palop, O., Simón, I., Martínez-Riquelme, A., Giménez-Pérez, G. and Vendrell, J. Diabetic neuropathy is associated with activation of the TNF- $\alpha$  system in subjects with type 1 diabetes mellitus, 525  
 Gooren, L.J.G. *see* Schaap, L.A.  
 Gordon, P. *see* Musso, C.  
 Gosnell, J. *see* Learoyd, D.L.  
 Gozansky, W.S., Lynn, J.S., Laudenslager, M.L. and Kohrt, W.M. Salivary cortisol determined by enzyme immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic-pituitary-adrenal axis activity, 336  
 Greco, E.A. *see* Isidori, A.M.  
 Greenman, Y., Tordjman, K., Osher, E., Veshchev, I., Shenkerman, G., Reider-Groswasser, I.I., Segev, Y., Ouaknine, G. and Stern, N. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth, 39  
 Gregersen, N. *see* Siggaard, C.  
 Gregory, J.W. *see* Davies, J.H.  
 Grella, E. *see* Rizzo, M.R.  
 Grella, R. *see* Rizzo, M.R.  
 Grobbee, D.E. *see* Lebrun, C.E.I.  
 Groome, N.P. *see* Al-Qahtani, A.  
 Grossman, A.B. *see* Chung, T.T.  
 Guerra, E. *see* Vitale, G.  
 Hana, V. *see* Silha, J.V.  
 Handelsman, D.J. *see* Meier, C.  
 Handelsman, D.J. *see* Nelson, A.E.  
 Haq, M. and Harmer, C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome, 87  
 Hardin, D.S., Rice, J., Doyle, M.E. and Pavia, A. Growth hormone improves protein catabolism and growth in prepubertal children with HIV infection, 259  
 Hardt, J. *see* Kahaly, G.J.  
 Harmer, C. *see* Haq, M.  
 Harris, P.E. *see* Yuen, K.C.J.  
 Harris, R.D. *see* Kinlaw, W.B.  
 Heickendorff, L. *see* Moosgaard, B.  
 de Herder, W.W. *see* van der Hoek, J.  
 Hindmarsh, P.C. *see* Mehta, A.  
 Hindmarsh, P.C. *see* Turton, J.P.G.  
 Hirschberg, A.L. *see* Berinder, K.  
 Hiura, Y. *see* Ueda, M.  
 Ho, K.K. *see* Nelson, A.E.  
 van der Hoek, J., van der Lelij, A.-J., Feelders, R.A., de Herder, W.W., Uitterlinden, P., Poon, K.W., Boerlin, V., Lewis, I., Krahnke, T., Hofland, L.J. and Lamberts, S.W. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients, 176  
 Hofland, L.J. *see* van der Hoek, J.

- Hong, A.W.L. *see* Thomas, G.N.
- Hong, S.J. *see* Kim, T.Y.
- Howe, C.J. *see* Nelson, A.E.
- Huang, C.-C. *see* Liu, R.-T.
- Hueston, W.J., King, D.E. and Geesey, M.E. Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism, 582
- Hughes, I.A. *see* Deeb, A.
- Hulting, A.-L. *see* Berinder, K.
- Hunt, P. *see* Soule, S.
- Hwang, R. *see* Lee, S.
- Idris, I., Srinivasan, R., Simm, A. and Page, R.C. Maternal hypothyroidism in early and late gestation: effects on neonatal and obstetric outcome, 560
- Iglesias, P., Acosta, M., Sánchez, R., Fernández-Reyes, M.J., Mon, C. and Diez, J.J. Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function, 66
- Ihm, S.H. *see* Oh, K.W.
- Inaba, M. *see* Ueda, M.
- Inder, W. *see* Soule, S.
- Ishikawa, T. *see* Ueda, M.
- Isidori, A. *see* Isidori, A.M.
- Isidori, A.M., Giannetta, E., Gianfrilli, D., Greco, E.A., Bonifacio, V., Aversa, A., Isidori, A., Fabbri, A. and Lenzi, A. Effects of testosterone on sexual function in men: results of a meta-analysis, 381
- Isidori, A.M., Giannetta, E., Greco, E.A., Gianfrilli, D., Bonifacio, V., Isidori, A., Lenzi, A. and Fabbri, A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis, 280
- Jadon, D. *see* Biswas, M.
- Jagannathan, N.R. *see* Sinha, S.
- Jallad, R. *see* Bronstein, M.
- Jallad, R.S., Musolino, N.R.C., Salgado, L.R. and Bronstein, M.D. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution, 168
- Jarkovska, Z. *see* Silha, J.V.
- Javor, E.D. *see* Musso, C.
- Jenney, M.E.M. *see* Davies, J.H.
- Jenuso, R. *see* Stagi, S.
- Jezkova, J. *see* Silha, J.V.
- Jobling, T. *see* Fuller, P.J.
- Johns, J. *see* Al-Qahtani, A.
- Jones, T.H. *see* Kapoor, D.
- de Jong, F.H. *see* Lebrun, C.E.I.
- Kahaly, G.J., Petrak, F., Hardt, J., Pitz, S. and Egle, U.T. Psychosocial morbidity of Graves' orbitopathy, 395
- Kaltsas, G. *see* Chrousos, G.P.
- Kang, M.I. *see* Oh, K.W.
- Kapoor, D., Malkin, C.J., Channer, K.S. and Jones, T.H. Androgens, insulin resistance and vascular disease in men, 239
- Karacan, I. *see* Aydin, T.
- Karanikas, G., Schuetz, M., Wahl, K., Paul, M., Kontur, S., Pietzschmann, P., Kletter, K., Dudczak, R. and Willheim, M. Relation of anti-TPO autoantibody titre and T-lymphocyte cytokine production patterns in Hashimoto's thyroiditis, 191
- Katuta, Y. *see* Liang, H.
- Kaw, G.J.-L. *see* Leow, M.K.-S.
- Kazlauskas, R. *see* Nelson, A.E.
- Kennedy, A. *see* Atkinson, A.B.
- Kim, D.J. *see* Lee, S.
- Kim, H.Y. *see* Kim, S.M.
- Kim, N.H. *see* Kim, S.M.
- Kim, S.C. *see* Kim, T.Y.
- Kim, S.G. *see* Kim, S.M.
- Kim, S.M., Lee, J., Ryu, O.H., Lee, K.W., Kim, H.Y., Seo, J.A., Kim, S.G., Kim, N.H., Baik, S.H., Choi, D.S. and Choi, K.M. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity, 594
- Kim, S.Y. *see* Kim, T.Y.
- Kim, T.Y., Kim, W.B., Song, J.Y., Rhee, Y.S., Gong, G., Cho, Y.M., Kim, S.Y., Kim, S.C., Hong, S.J. and Shong, Y.K. The BRAF<sup>V600E</sup> mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma, 588
- Kim, W.B. *see* Kim, T.Y.
- King, D.E. *see* Hueston, W.J.
- King, D.E., Scott, S.M., Maue, R.A., Memoli, V.A., Harris, R.D., Daniels, G.H., Porter, D.M., Belloni, D.R., Spooner, E.T., Ernesti, M.M. and Noll, W.W. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma, 676
- Kistorp, C. *see* Øgaard, C.G.
- Kletter, K. *see* Karanikas, G.
- Klose, M., Lange, M., Kosteljanetz, M., Poulsen, L. and Feldt-Rasmussen, U. Adrenocortical insufficiency after pituitary surgery: an audit of the reliability of the conventional short synacthen test, 499
- Kobayashi, J. *see* Liang, H.
- Kohrt, W.M. *see* Gozansky, W.S.
- Kontur, S. *see* Karanikas, G.
- Koppeschaar, H.P.F. *see* Yuen, K.C.J.
- Kosteljanetz, M. *see* Klose, M.
- Krahnke, T. *see* van der Hoek, J.
- Krsek, M. *see* Silha, J.V.
- Kullmann, V. *see* Mai, K.
- Kumar, M. *see* Sinha, S.
- Kumar, V. *see* Sinha, S.
- Kumeda, Y. *see* Ueda, M.
- Kwek, D.S.-K. *see* Leow, M.K.-S.
- L'Hermite-Balériaux, M. *see* Leproult, R.
- Lam, C.W.K. *see* Ng, P.C.
- Lam, C.W.K. *see* Thomas, G.N.
- Lamberts, S.W. *see* van der Hoek, J.
- Lamberts, S.W.J. *see* Lebrun, C.E.I.
- Lambrecht, F.Y. *see* Darcan, Ş.
- Lange, M. *see* Klose, M.
- Lapi, E. *see* Stagi, S.
- Lapi, P. *see* Barbaro, D.
- Lau, E. *see* Thomas, G.N.
- Laudenslager, M.L. *see* Gozansky, W.S.
- Lauri, E. *see* Morpurgo, P.S.



- Lavis, V.R. *see* Picosol, M.K.
- Leary, D.L., Gosnell, J., Elston, M.S., Saurine, T.J., Richardson, A.-L., Delbridge, L.W., Conaglen, J.V. and Robinson, B.G. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations, 636
- Lebrun, C.E.I., van der Schouw, Y.T., de Jong, F.H., Pols, H.A.P., Grobbee, D.E. and Lamberts, S.W.J. Endogenous oestrogens are related to cognition in healthy elderly women, 50
- Lee, C.H. *see* Ng, P.C.
- Lee, J. *see* Kim, S.M.
- Lee, J. *see* Lee, S.
- Lee, K.W. *see* Kim, S.M.
- Lee, L.S.-U. *see* Leow, M.K.-S.
- Lee, S., Hwang, R., Lee, J., Rhee, Y., Kim, D.J., Chung, U.-I. and Lim, S.-K. Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH-independent macronodular adrenal hyperplasia, 625
- Lee, W.Y. *see* Oh, K.W.
- Lee, Y.S. *see* Deeb, A.
- Leedman, P.J. *see* Walsh, J.P.
- van der Lelij, A.-J. *see* van der Hoek, J.
- Lenzi, A. *see* Isidori, A.M.
- Leow, M.K.-S., Kwek, D.S.-K., Ng, A.W.-K., Ong, K.-C., Kaw, G.J.-L. and Lee, L.S.-U. Hypocortisolism in survivors of severe acute respiratory syndrome (SARS), 197
- Leprout, R., Van Onderbergen, A., L'Hermite-Balériaux, M., Van Cauter, E. and Copinschi, G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men, 298
- Leselbaum, A. *see* Bronstein, M.
- Lewis, I. *see* van der Hoek, J.
- Li, C.-L. *see* Liu, R.-T.
- Liang, H., Murase, Y., Katuta, Y., Asano, A., Kobayashi, J. and Mabuchi, H. Association of LMNA 1908C/T polymorphism with cerebral vascular disease and diabetic nephropathy in Japanese men with type 2 diabetes, 317
- Liberati, C.D. *see* Canale, D.
- Lightman, S. *see* Crown, A.
- Lim, S.-K. *see* Lee, S.
- de Lima Zollner, R. *see* Ferraroni, N.R.
- Lips, P. *see* Arwert, L.I.
- Lips, P. *see* Puts, M.T.E.
- Lips, P. *see* Schaap, L.A.
- Liu, H., Bravata, D.M., Cabaccan, J., Raff, H. and Ryzen, E. Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans, 642
- Liu, P.Y. *see* Meier, C.
- Liu, P.Y., Wang, C. and Swerdloff, R.S. Male sex matters, 601
- Liu, R.-T., Chen, Y.-J., Chou, F.-F., Li, C.-L., Wu, W.-L., Tsai, P.-C., Huang, C.-C. and Cheng, J.-T. No correlation between BRAF<sup>V600E</sup> mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan, 461
- Locci, M.T. *see* Bogazzi, F.
- Lombardi, G. *see* Colao, A.
- Lombardi, G. *see* Vitale, G.
- Losi, S. *see* Stagi, S.
- Luthra, K. *see* Sinha, S.
- Lynn, J.S. *see* Gozansky, W.S.
- Möhl, M. *see* Mai, K.
- Mabuchi, H. *see* Liang, H.
- Macchia, E. *see* Canale, D.
- Mai, K. *see* Bobbert, T.
- Mai, K., Kullmann, V., Bobbert, T., Maser-Gluth, C., Möhl, M., Bähr, V., Pfeiffer, A.F.H., Spranger, J. and Diederich, S. *In vivo* activity of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 and free fatty acid-induced insulin resistance, 442
- Malkin, C.J. *see* Kapoor, D.
- Manguso, F. *see* Palomba, S.
- Manoliu, R.A. *see* Arwert, L.I.
- Mansour, E. *see* Ferraroni, N.R.
- Maravall, J. *see* Vilarrasa, N.
- Marcovecchio, M. *see* Mohn, A.
- Marek, J. *see* Silha, J.V.
- Martínez-Riquelme, A. *see* González-Clemente, J.M.
- Martino, E. *see* Bogazzi, F.
- Martino, E. *see* Canale, D.
- Martins, I.J. *see* Ng, T.W.K.
- Marzullo, P. *see* Colao, A.
- Maser-Gluth, C. *see* Bobbert, T.
- Maser-Gluth, C. *see* Mai, K.
- Mason, C. *see* Deeb, A.
- Mattanza, C. *see* Cappelli, C.
- Maue, R.A. *see* Kinlaw, W.B.
- Mauricio, D. *see* González-Clemente, J.M.
- McCance, D.R. *see* Atkinson, A.B.
- McEwan, P. *see* Biswas, M.
- McMillan, C.V. *see* Razvi, S.
- McNeilage, J. *see* Fuller, P.J.
- Megia, A. *see* González-Clemente, J.M.
- Megia, A. *see* Vilarrasa, N.
- Mehta, A. *see* Turton, J.P.G.
- Mehta, A., Hindmarsh, P.C., Stanhope, R.G., Turton, J.P.G., Cole, T.J., Preece, M.A. and Dattani, M.T. The role of growth hormone in determining birth size and early postnatal growth, using congenital growth hormone deficiency (GHD) as a model, 223
- Meier, C., Liu, P.Y., Handelsman, D.J. and Seibel, M.J. Endocrine regulation of bone turnover in men, 603
- Melis, D., Parenti, G., Gatti, R., Casa, R.D., Parini, R., Riva, E., Burlina, A.B., Vici, C.D., Di Rocco, M., Furlan, F., Torcoletti, M., Papadia, F., Donati, A., Benigno, V. and Andria, G. Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study, 19
- Melsen, F. *see* Moosgaard, B.
- Memoli, V.A. *see* Kinlaw, W.B.
- Mencacci, M. *see* Celi, F.
- Meucci, G. *see* Barbaro, D.
- Michelangeli, V. *see* Walsh, J.P.
- Micheletti, L. *see* Cappelli, C.
- Mielke, K.L. *see* Soares-Welch, C.
- Milone, F. *see* Vitale, G.

- Minuto, F. *see* Resmini, E.
- Misra, A. *see* Sinha, S.
- Mohn, A., Di Marzio, D., Giannini, C., Capanna, R., Marcovecchio, M. and Chiarelli, F. Alterations in the oxidant-antioxidant status in prepubertal children with growth hormone deficiency: effect of growth hormone replacement therapy, 537
- Mon, C. *see* Iglesias, P.
- Monson, J.P. *see* Chung, T.T.
- Moosgaard, B., Vestergaard, P., Heickendorff, L., Melsen, F., Christiansen, P. and Mosekilde, L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism, 506
- Morpurgo, P.S., Cappiello, V., Verga, U., Vicentini, L., Vaghi, I., Lauri, E., Nebuloni, M., Beck-Peccoz, P. and Spada, A. Ghrelin in human medullary thyroid carcinomas, 437
- Moschini, C. *see* Canale, D.
- Mosekilde, L. *see* Moosgaard, B.
- Mourits, M.P. *see* Wakelkamp, I.M.M.J.
- Mul, D., Oostdijk, W., Waelkens, J.J.J. and Drop, S.L.S. Final height after treatment of early puberty in short adopted girls with gonadotrophin releasing hormone agonist with or without growth hormone, 185
- Murase, Y. *see* Liang, H.
- Murgatroyd, P.R. *see* Yuen, K.C.J.
- Murphy, L.J. *see* Silha, J.V.
- Muscelli, E.O. *see* Ferraroni, N.R.
- Musolino, N. *see* Bronstein, M.
- Musolino, N.R.C. *see* Jallad, R.S.
- Musso, C., Shawker, T., Cochran, E., Javor, E.D., Young, J. and Gorden, P. Clinical evidence that hyperinsulinaemia independent of gonadotropins stimulates ovarian growth, 73
- Muttukrishna, S. *see* Al-Qahtani, A.
- Nagasaki, T. *see* Ueda, M.
- Nebuloni, M. *see* Morpurgo, P.S.
- Nelson, A.E., Howe, C.J., Nguyen, T.V., Seibel, M.J., Baxter, R.C., Handelsman, D.J., Kazlauskas, R. and Ho, K.K. Erythropoietin administration does not influence the GH-IGF axis or makers of bone turnover in recreational athletes, 305
- Neri, A.S. *see* Stagi, S.
- Ng, A.W.-K. *see* Leow, M.K.-S.
- Ng, P.C., Lee, C.H., Lam, C.W.K., Chan, I.H.S., Wong, E. and Fok, T.F. Ghrelin in preterm and term newborns: relation to anthropometry, leptin and insulin, 217
- Ng, T.W.K., Watts, G.F., Stuckey, B.G.A., Ching, H.L., Chan, D.C.F., Uchida, Y., Sakai, N., Yamashita, S., Martins, I.J., Redgrave, T.G. and Barrett, P.H.R. Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?, 650
- Nguyen, T.V. *see* Nelson, A.E.
- Nicoletti, A., Baldazzi, L., Balsamo, A., Barp, L., Pirazzoli, P., Gennari, M., Radetti, G., Cacciari, E. and Cicognani, A. *SRD5A2* gene analysis in an Italian population of under-masculinized 46,XY subjects, 475
- Nicoletti, G. *see* Rizzo, M.R.
- Nielsen, S.L. *see* Øgard, C.G.
- Nishizawa, Y. *see* Ueda, M.
- Noll, W.W. *see* Kinlaw, W.B.
- O'Leary, P. *see* Walsh, J.P.
- Obach, R. *see* Bronstein, M.
- Øgard, C.G., Engelmann, M.D., Kistorp, C., Nielsen, S.L. and Vestergaard, H. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism, 493
- Oh, K.W., Lee, W.Y., Rhee, E.J., Baek, K.H., Yoon, K.H., Kang, M.I., Yun, E.J., Park, C.Y., Ihm, S.H., Choi, M.G., Yoo, H.J. and Park, S.W. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men, 131
- Ong, K.-C. *see* Leow, M.K.-S.
- Onoda, N. *see* Ueda, M.
- Oostdijk, W. *see* Mul, D.
- Orio Jr, F. *see* Palomba, S.
- Orlander, P.R. *see* Pocolos, M.K.
- Orsini, P. *see* Barbaro, D.
- Osher, E. *see* Greenman, Y.
- Otto, B. *see* Bobbert, T.
- Ouaknine, G. *see* Greenman, Y.
- Ozcan, O., Cakir, E., Yaman, H., Akgul, E.O., Erturk, K., Beyhan, Z., Bilgi, C. and Erbil, M.K. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism, 203
- Özener, Ç. *see* Yavuz, D.
- Page, R.C. *see* Idris, I.
- Palomba, S., Orio Jr, F., Falbo, A., Russo, T., Caterina, G., Manguso, F., Tolino, A., Colao, A. and Zullo, F. Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome, 631
- Pandey, R.M. *see* Sinha, S.
- Panzarella, T. *see* Brierley, J.
- Paolisso, G. *see* Rizzo, M.R.
- Papadia, F. *see* Melis, D.
- Papi, F. *see* Celi, F.
- Parenti, G. *see* Melis, D.
- Parini, R. *see* Melis, D.
- Park, C.Y. *see* Oh, K.W.
- Park, S.W. *see* Oh, K.W.
- Pasquali, D. *see* De Bellis, A.
- Pasquini, C. *see* Barbaro, D.
- Paul, M. *see* Karanikas, G.
- Pavia, A. *see* Hardin, D.S.
- Pedersen, E.B. *see* Siggaard, C.
- Pemberton, C. *see* Soule, S.
- Perrino, S. *see* De Bellis, A.
- Perroud, A.P. *see* Ferraroni, N.R.
- Petrak, F. *see* Kahaly, G.J.
- Pezzino, V. *see* Tita, P.
- Pfeiffer, A.F.H. *see* Bobbert, T.
- Pfeiffer, A.F.H. *see* Mai, K.
- Pocolos, M.K., Lavis, V.R. and Orlander, P.R. Milk-alkali syndrome

- is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients, 566
- Pietschmann, P. *see* Karanikas, G.
- Pinchera, A. *see* Canale, D.
- Pirazzoli, P. *see* Nicoletti, A.
- Pirola, I. *see* Cappelli, C.
- Pitz, S. *see* Kahaly, G.J.
- Pivonello, R. *see* Colao, A.
- Pivonello, R. *see* Vitale, G.
- Plowman, P.N. *see* Chung, T.T.
- Pluijm, S.M.F. *see* Schaap, L.A.
- Pols, H.A.P. *see* Lebrun, C.E.I.
- Poon, K.W. *see* van der Hoek, J.
- Porter, D.M. *see* Kinlaw, W.B.
- Poulsen, L. *see* Klose, M.
- Preece, M.A. *see* Mehta, A.
- Prummel, M.F. *see* Wakelkamp, I.M.M.J.
- Puts, M.T.E., Visser, M., Twisk, J.W.R., Deeg, D.J.H. and Lips, P. Endocrine and inflammatory markers as predictors of frailty, 403
- Radetti, G. *see* Camilot, M.
- Radetti, G. *see* Nicoletti, A.
- Raff, H. *see* Liu, H.
- Raggi, F. *see* Bogazzi, F.
- Ragno, E. *see* Rizzo, M.R.
- Ramis, J. *see* Bronstein, M.
- Rapa, A. *see* Camilot, M.
- Rathi, M. *see* Sinha, S.
- Raudsepp, S. *see* Soule, S.
- Raza, J. *see* Turton, J.P.G.
- Razvi, S., McMillan, C.V. and Weaver, J.U. Instruments used in measuring symptoms, health status and quality of life in hypothyroidism: a systematic qualitative review, 617
- Redgrave, T.G. *see* Ng, T.W.K.
- Rees, D.A. *see* Biswas, M.
- Reider-Groswasser, I.I. *see* Greenman, Y.
- Resmini, E., Barreca, A., Ferone, D., Giusti, M., Sidoti, M. and Minuto, F. Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients, 294
- Reynolds, R.M. and Seckl, J.R. Hyponatraemia for the clinical endocrinologist, 366
- Rhee, E.J. *see* Oh, K.W.
- Rhee, Y. *see* Lee, S.
- Rhee, Y.S. *see* Kim, T.Y.
- Rice, J. *see* Hardin, D.S.
- Richardson, A.-L. *see* Learoyd, D.L.
- Richart, C. *see* González-Clemente, J.M.
- Richart, C. *see* Vilarrasa, N.
- Rittig, S. *see* Siggaard, C.
- Riva, E. *see* Melis, D.
- Rizzo, M.R., Paolisso, G., Grella, R., Barbieri, M., Grella, E., Ragno, E., Grella, R., Nicoletti, G. and D'andrea, F. Is dermolipectomy effective in improving insulin action and lowering inflammatory markers in obese women?, 253
- Robertson, G.L. *see* Siggaard, C.
- Robinson, B.G. *see* Learoyd, D.L.
- Roos, J.C. *see* Arwert, L.I.
- Rosei, E.A. *see* Cappelli, C.
- Rosicka, M. *see* Silha, J.V.
- Russo, D. *see* Bogazzi, F.
- Russo, T. *see* Palomba, S.
- Ryu, O.H. *see* Kim, S.M.
- Ryzen, E. *see* Liu, H.
- Saeed, P. *see* Wakelkamp, I.M.M.J.
- Sahin, Z. *see* Aydin, T.
- Sakai, N. *see* Ng, T.W.K.
- Salgado, L.R. *see* Jallad, R.S.
- Salti, R. *see* Stagi, S.
- Sánchez, R. *see* Iglesias, P.
- Sanderson, J.E. *see* Thomas, G.N.
- Santilli, E. *see* Celi, F.
- Sardella, C. *see* Bogazzi, F.
- Saurine, T.J. *see* Learoyd, D.L.
- Savastano, S. *see* Vitale, G.
- Scanlon, M.F. *see* Biswas, M.
- Schaap, L.A., Pluijm, S.M.F., Smit, J.H., van Schoor, N.M., Visser, M., Gooren, L.J.G. and Lips, P. The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women, 152
- van der Schouw, Y.T. *see* Lebrun, C.E.I.
- van Schoor, N.M. *see* Schaap, L.A.
- Schuetz, M. *see* Karanikas, G.
- Scollo, C. *see* Tita, P.
- Scott, S.M. *see* Kinlaw, W.B.
- Seckl, J.R. *see* Reynolds, R.M.
- Segev, Y. *see* Greenman, Y.
- Seibel, M.J. *see* Meier, C.
- Seibel, M.J. *see* Nelson, A.E.
- Seo, J.A. *see* Kim, S.M.
- Shawker, T. *see* Musso, C.
- Shenkerman, G. *see* Greenman, Y.
- Sheridan, B. *see* Atkinson, A.B.
- Shong, Y.K. *see* Kim, T.Y.
- Sidoti, M. *see* Resmini, E.
- Siggaard, C., Christensen, J.H., Corydon, T.J., Rittig, S., Robertson, G.L., Gregersen, N., Bolund, L. and Pedersen, E.B. Expression of three different mutations in the arginine vasopressin gene suggests genotype-phenotype correlation in familial neurohypophyseal diabetes insipidus kindreds, 207
- Silha, J.V., Krsek, M., Hana, V., Marek, J., Weiss, V., Jezkova, J., Rosicka, M., Jarkovska, Z. and Murphy, L.J. The effects of growth hormone status on circulating levels of vascular growth factors, 79
- Simón, I. *see* González-Clemente, J.M.
- Simón, I. *see* Vilarrasa, N.
- Simi, U. *see* Barbaro, D.
- Simm, A. *see* Idris, I.
- Sinha, S., Rathi, M., Misra, A., Kumar, V., Kumar, M., Jagannathan, N.R., Pandey, R.M., Dwivedi, M. and Luthra, K. Subclinical inflammation and soleus muscle intramyocellular lipids in healthy Asian Indian males, 350
- Sinisi, A.A. *see* De Bellis, A.



- Sirikçi, Ö. *see* Yavuz, D.
- Smit, J.H. *see* Schaap, L.A.
- Smith, J. *see* Biswas, M.
- Soares-Welch, C., Mielke, K.L., Bowers, C.Y. and Veldhuis, J.D. Short-term testosterone supplementation does not activate GH and IGF-I production in postmenopausal women, 32
- Soler, J. *see* Vilarrosa, N.
- Song, J.Y. *see* Kim, T.Y.
- Soule, S., Pemberton, C., Hunt, P., Cole, D., Raudsepp, S. and Inder, W. Prandial regulation of ghrelin secretion in humans: does glucagon contribute to the preprandial increase in circulating ghrelin?, 412
- Spada, A. *see* Morpurgo, P.S.
- Spooner, E.T. *see* Kinlaw, W.B.
- Spranger, J. *see* Bobbert, T.
- Spranger, J. *see* Mai, K.
- Srinivasan, R. *see* Idris, I.
- Stackenäs, I. *see* Berinder, K.
- Stagi, S., Bindi, G., Neri, A.S., Lapi, E., Losi, S., Jenuso, R., Salti, R. and Chiarelli, F. Thyroid function and morphology in patients affected by Williams syndrome, 456
- Stanhope, R.G. *see* Mehta, A.
- Starzyk, J. *see* Turton, J.P.G.
- Stern, N. *see* Greenman, Y.
- Stettler, C. *see* Trepp, R.
- Stuckey, B.G.A. *see* Ng, T.W.K.
- Swerdlow, R.S. *see* Liu, P.Y.
- Tahara, H. *see* Ueda, M.
- Tambascia, M. *see* Ferraroni, N.R.
- Tatò, L. *see* Camilot, M.
- Teofoli, F. *see* Camilot, M.
- Themmen, A.P.N. *see* Al-Qahtani, A.
- Thomas, G.N., Hong, A.W.L., Tomlinson, B., Lau, E., Lam, C.W.K., Sanderson, J.E. and Woo, J. Effects of Tai Chi and resistance training on cardiovascular risk factors in elderly Chinese subjects: a 12-month longitudinal, randomized, controlled intervention study, 663
- Thomas, P.Q. *see* Turton, J.P.G.
- Tironi, A. *see* Cappelli, C.
- Tita, P., Ambrosio, M.R., Scollo, C., Carta, A., Gangemi, P., Bondanelli, M., Vigneri, R., Uberti, E.C.D. and Pezzino, V. High prevalence of differentiated thyroid carcinoma in acromegaly, 161
- Tiulpakov, A. *see* Turton, J.P.G.
- Tolino, A. *see* Palomba, S.
- Tomlinson, B. *see* Thomas, G.N.
- Topçu, G. *see* Yavuz, D.
- Torcoletti, M. *see* Melis, D.
- Tordjman, K. *see* Greenman, Y.
- Tortora, F. *see* Colao, A.
- Trepp, R., Everts, R., Stettler, C., Fischli, S., Allemann, S., Webb, S.M. and Christ, E.R. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL), 103, 238
- Tsai, P.-C. *see* Liu, R.-T.
- Tsang, R. *see* Brierley, J.
- Turton, J.P.G. *see* Mehta, A.
- Turton, J.P.G., Mehta, A., Raza, J., Woods, K.S., Tiulpakov, A., Cassar, J., Chong, K., Thomas, P.Q., Eunice, M., Ammini, A.C., Bouloux, P.M., Starzyk, J., Hindmarsh, P.C. and Dattani, M.T. Mutations within the transcription factor *PRO1* are rare in a cohort of patients with sporadic combined pituitary hormone deficiency (CPHD), 10
- Twickler, T.B. *see* Yuen, K.C.J.
- Twisk, J.W.R. *see* Arwert, L.I.
- Twisk, J.W.R. *see* Puts, M.T.E.
- Uberti, E.C.D. *see* Tita, P.
- Uchida, Y. *see* Ng, T.W.K.
- Ueda, M., Inaba, M., Kumeda, Y., Nagasaki, T., Hiura, Y., Tahara, H., Onoda, N., Ishikawa, T. and Nishizawa, Y. The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves' disease relapse, 657
- Uitterlinden, P. *see* van der Hoeke, J.
- Ultimieri, F. *see* Bogazzi, F.
- Unak, P. *see* Darcin, Ş.
- Undén, A.-L., Eloffson, S. and Brismar, K. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study, 94
- Vaghi, I. *see* Morpurgo, P.S.
- Van Cauter, E. *see* Leproult, R.
- Van Onderbergen, A. *see* Leproult, R.
- Veldhuis, J.D. *see* Soares-Welch, C.
- Velloso, L.A. *see* Ferraroni, N.R.
- Vendrell, J. *see* González-Clemente, J.M.
- Vendrell, J. *see* Vilarrosa, N.
- Verga, U. *see* Morpurgo, P.S.
- Veshchev, I. *see* Greenman, Y.
- Vestergaard, H. *see* Øgaard, C.G.
- Vestergaard, P. *see* Moosgaard, B.
- Vicentini, L. *see* Morpurgo, P.S.
- Vici, C.D. *see* Melis, D.
- Vigneri, R. *see* Tita, P.
- Vilarrosa, N., Vendrell, J., Maravall, J., Broch, M., Estepa, A., Megia, A., Soler, J., Simón, I., Richart, C. and Gómez, J.M. Distribution and determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population, 329
- Visser, J.A. *see* Al-Qahtani, A.
- Visser, M. *see* Puts, M.T.E.
- Visser, M. *see* Schaap, L.A.
- Vitale, G., Pivonello, R., Auriemma, R.S., Guerra, E., Milone, F., Savastano, S., Lombardi, G. and Colao, A. Hypertension in acromegaly and in the normal population: prevalence and determinants, 470
- Waelkens, J.J.J. *see* Mul, D.
- Wahl, K. *see* Karanikas, G.
- Wakelkamp, I.M.M.J., Baldeschi, L., Saeed, P., Mourits, M.P., Prummel, M.F. and Wiersinga, W.M. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial, 323
- Walker, D. *see* Chung, T.T.
- Walsh, J.P., Bremner, A.P., Bulsara, M.K., O'leary, P., Leedman, P.J., Feddema, P. and Michelangeli, V. Thyroid dysfunction and serum lipids: a community-based study, 670

- Wang, C. *see* Liu, P.Y.
- Watts, G.F. *see* Ng, T.W.K.
- Weaver, J.U. *see* Razvi, S.
- Weaver, J.U. Obesity, cytokines and the search for beauty, 251
- Webb, S.M. *see* Trepp, R.
- Weiss, V. *see* Silha, J.V.
- White, D.K. *see* Yuen, K.C.J.
- Wiersinga, W.M. *see* Wakelkamp, I.M.M.J.
- Wiggam, M.I. *see* Atkinson, A.B.
- Willheim, M. *see* Karanikas, G.
- Wong, E. *see* Ng, P.C.
- Woo, J. *see* Thomas, G.N.
- Woods, K.S. *see* Turton, J.P.G.
- Wu, W.-L. *see* Liu, R.-T.
- Xing, M.Z. The T1799A *BRAF* mutation is not a germline mutation in familial nonmedullary thyroid cancer, 263
- Yalman, O. *see* Darcan, Ş.
- Yaman, H. *see* Ozcan, O.
- Yamashita, S. *see* Ng, T.W.K.
- Yavuz, D., Topçu, G., Özener, Ç., Akalın, S. and Sirikçi, Ö. Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy, 520
- Yoo, H.J. *see* Oh, K.W.
- Yoon, K.H. *see* Oh, K.W.
- Young, J. *see* Musso, C.
- Yuen, K.C.J., Frystyk, J., White, D.K., Twickler, T.B., Koppeschaar, H.P.F., Harris, P.E., Fryklund, L., Murgatroyd, P.R. and Dunger, D.B. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency, 428
- Yun, E.J. *see* Oh, K.W.
- Zullo, F. *see* Palomba, S.

# Subject index to Volume 63

- ACE-inhibitor therapy  
renal disease in GSD1 19
- Acromegaly  
cabergoline and somatostatin analogues (Letter) 477  
differentiated thyroid carcinoma 161  
effects of therapy on GH secretion 294  
GH status and vascular growth factors 79  
hypertension in 470  
long-term somatostatin analogue therapy 342  
octreotide therapy 168, 176, 342  
pharmacokinetic profile of lanreotide Autogel® 514  
quality of life questionnaire 103  
reduced apoptosis in colonic mucosa 682
- AcroQol questionnaire for acromegaly 103
- ACTH  
familial ACTH-independent macronodular adrenal hyperplasia 624  
in Nelson's syndrome and Cushing's disease (Letter) 232
- Addison's disease  
in hyponatraemia (Review) 368
- Adiponectin  
BMD in men 131  
in regulation of body composition 329
- Adiposity  
ghrelin and galanin in children with IDDM 139
- ADMA (asymmetric dimethylarginine)  
thyroxine replacement and cardiovascular risk 203
- Adrenal hyperplasia  
familial ACTH-independent macronodular 624
- Adrenal insufficiency (primary and secondary)  
in hyponatraemia (Review) 368
- Adrenocortical insufficiency  
role of synacthen test 499
- Age  
androgens, insulin resistance and vascular disease in men (Review) 241  
effects of testosterone in middle-aged men 280  
endocrine regulation of bone turnover in men (Review) 604  
regulation of body composition 329  
see also Elderly subjects
- Agomelatine  
phase-shifting effects in older men 298
- ALL  
childhood, skeletal morbidity (Review) 1
- Anabolic steroids  
androgens, insulin resistance and vascular disease in men (Review) 244
- Androgenicity  
androgen receptor polymorphism 356
- Androgens  
insulin resistance and vascular disease in men (Review), 239  
partial androgen insensitivity syndrome 56
- Ankylosing spondylitis  
bone loss in men 467
- Anthropometry  
ghrelin in preterm and term newborns 217
- Anti-Müllerian hormone  
development and evaluation of assay 267
- Antipituitary antibodies  
in GHD and autoimmune endocrine diseases 45
- Apoptosis  
reduced, in acromegalic colon mucosa 682
- Arginine vasopressin (AVP)  
genotype-phenotype correlation in diabetes insipidus 207
- Atherosclerosis  
arterial stiffness and osteoprotegerin 594  
in primary hyperparathyroidism 493
- Athletes  
adaptation of HPA axis during endurance training 530  
erythropoietin administration 305
- Autoantibodies  
in Hashimoto's thyroiditis 191
- Autoimmune diseases  
antipituitary antibodies 45
- Blood pressure  
ambulatory monitoring and thyroid function 66
- Body composition  
adiponectin, resistin and ghrelin in regulation 329  
effects of low-dose GH in severe GHD 428  
effects of testosterone in middle-aged men 280  
long-term effects of GH therapy 31
- Bone  
BMD, and adipocytokines in men 131  
BMD, long-term effects of GH therapy 31  
BMD, in primary hyperparathyroidism 506  
endocrine regulation of turnover in men (Review) 602  
loss, in ankylosing spondylitis 467  
in management of glucocorticoid deficiency (Review) 486  
metabolism, in childhood ALL (Review) 1  
metabolism, effects of testosterone in middle-aged men, 280  
metabolism, and erythropoietin administration in athletes 305
- Bromocriptine  
withdrawal of therapy for microprolactinomas 26
- Cabergoline  
in acromegaly (Letter) 477  
withdrawal of therapy for microprolactinomas 26
- Calciotropic hormones  
in regulation of bone turnover in men (Review) 608
- Calcium  
arterial stimulation in insulinoma localization (Letter) 480
- Cardiovascular risk  
androgens and insulin resistance in men (Review) 239

- effects of Tai Chi and resistance training 662
- effects of thyroxine replacement 203
- gender and IGFBP-1 94
- GHD and type 2 diabetes (Letter) 700
- LMNA 1908C/T polymorphism in type 2 diabetes 317
- low-dose GH in severe GHD 428
- management of glucocorticoid deficiency (Review) 488
- osteoprotegerin levels 594
- in primary hyperparathyroidism 493
- in subclinical hypothyroidism 582
- Cerebral vascular disease
  - LMNA 1908C/T polymorphism in type 2 diabetes 317
- Chemotherapy
  - in childhood ALL (Review) 1
- Children
  - alterations in oxidant-antioxidant status in GHD 537
  - evaluation of iodine deficiency status 543
  - GH, growth and protein catabolism in HIV infection 259
  - ghrelin and galanin in type 1 diabetes mellitus 139
  - sex of rearing and PAIS 56
  - skeletal morbidity in ALL (Review) 1
  - treatment of early puberty in girls 185
- Chylomicron
  - remnant catabolism in type 2 diabetes 649
- Circadian rhythm
  - phase-shifts in older men 298
- Clomiphene citrate
  - in ovulation induction in PCOS 630
- Cognition
  - oestrogens in elderly women 50
- Colon mucosa
  - reduced apoptosis in acromegaly 682
- Cortisol
  - management of glucocorticoid deficiency (Review) 484
  - salivary, assay of HPA axis activity 336
  - salivary, effects of lemon juice on assays (Letter) 478
  - salivary, elevated in type 2 diabetes 641
- Cortisone
  - management of glucocorticoid deficiency (Review) 484
- CPHD (combined pituitary hormone deficiency)
  - genetic factors 10, (Review) 121
- C-reactive protein (CRP)
  - as predictor of frailty 403
  - soleus muscle IMCL and insulin sensitivity 350
  - in subclinical hypothyroidism 582
- CT (computed tomography)
  - surveillance imaging for extrapituitary tumours 274
- Cushing's disease/syndrome
  - ACTH secretory process (Letter) 232
  - familial ACTH-independent macronodular adrenal hyperplasia 624
  - long-term remission rates post-surgery 549
  - long-term rosiglitazone (Letter) 118
  - with tuberous sclerosis (Letter) 693
- Cytokines
  - in Hashimoto's thyroiditis 191
  - IL-13 and chromosome studies in Graves' disease 695
  - response following dermolipectomy 253, (Commentary) 251
  - TNF- $\alpha$  in diabetic neuropathy 525
- Dermolipectomy
  - insulin action and inflammatory markers 253, (Commentary) 251
- DHEA
  - androgens, insulin resistance and vascular disease in men (Review) 245
- Diabetes insipidus
  - AVP gene 207
  - extrapontine myelinolysis and acute severe hyponatraemia (Letter) 233
- Diabetes mellitus
  - ghrelin and galanin in IDDM in children 139
  - osteoprotegerin and cardiovascular risk 594
  - type 1, and diabetic neuropathy 525
  - type 2, androgens, insulin resistance and vascular disease in men (Review) 239
  - type 2, elevated salivary cortisol in elderly males 641
  - type 2, GHD and vascular complications (Letter) 700
  - type 2, LMNA 1908C/T polymorphism 317
  - type 2, statins and chylomicron remnant catabolism 649
  - type 2, subclinical hypothyroidism in women (Letter) 479
- Dialysis patients
  - erythropoietin administration in athletes 305
- Dietary factors
  - in childhood ALL (Review) 1
- Dopamine agonist therapy
  - nonfunctioning pituitary adenomas 39
  - withdrawal and microprolactinomas 26
- Doping tests
  - erythropoietin administration in athletes 305
- EIA (enzyme immunoassay)
  - salivary cortisol and HPA axis activity 336
- Elderly subjects
  - agomelatine and phase-shifting in men 298
  - elevated salivary cortisol in type 2 diabetes 641
  - oestrogens and cognition in women 50
  - predictors of frailty 403
  - sex hormones, mobility and muscle strength 152
  - Tai Chi, resistance training and cardiovascular risk 662
- ELISA
  - for anti-Müllerian hormone 267
- Endocrinopathy
  - following SARS 197, (Commentary) 363
- Endurance training
  - adaptation of HPA axis 530
- Erectile function
  - effects of testosterone 381, (Commentary) 600
- Erythropoietin
  - administration in athletes 305

- Exercise  
 endurance training and adaptation of HPA axis 530  
 Tai Chi, resistance training and cardiovascular risk 662
- Falls  
 sex hormones and gender in the elderly 152
- Fine-needle aspiration cytology  
 nonpalpable thyroid nodules 688
- Frailty  
 endocrine and inflammatory markers as predictors 403
- Free fatty acids (FFAs)  
 11B-HSD1 activity 442
- Galanin  
 in children with IDDM 139
- Gender  
 cardiovascular risk and IGFBP-1 94  
 see also Men; Women
- Genetics  
 androgen receptor polymorphism and androgenicity 356  
 BRAF<sup>V600E</sup> mutation in papillary thyroid carcinomas 461, 588  
 combined pituitary hormone deficiency 10, (Review) 121  
 differential diagnosis of under-masculinization 375  
 familial AIMAH and expression of vasopressin receptors 624  
 familial nonmedullary thyroid cancer and T1799A BRAF mutation 263  
 genotype-phenotype correlation in diabetes insipidus 207  
 GHD (Review) 121  
 GHD, type 2 diabetes and vascular complications (Letter) 700  
 IL-13 and chromosome studies in Graves' disease 695  
 LMNA 1908C/T polymorphism in type 2 diabetes 317  
 partial androgen insensitivity syndrome 56  
 prophylactic thyroidectomy in MEN 2A kindreds 635  
 seladin-1 expression in ovarian tissue 111  
 susceptibility loci for Graves' disease (Letter) 232  
 TSH receptor and TSH resistance 146  
 unique MEN type 2A phenotype 675
- GH  
 axis, and erythropoietin administration in athletes 305  
 effects on birth size and early growth 223  
 effects of therapeutic modalities in acromegaly 294  
 growth and protein catabolism in HIV-infected children 259  
 low-dose, in severe GHD 428  
 prandial regulation 412  
 status and vascular growth factors 79  
 surveillance imaging for extrapituitary tumours 274  
 testosterone supplementation in postmenopausal women 32  
 therapy, long-term effects in men 310  
 treatment of early puberty in girls 185
- GHD  
 alterations in oxidant-antioxidant status 537  
 antipituitary antibodies 45  
 congenital, effects on birth size and early growth 223  
 effects of low-dose GH 428  
 effects on vascular growth factors 79  
 genetic factors (Review) 121  
 type 2 diabetes and vascular complications (Letter) 700
- Ghrelin  
 BMD in men 131  
 in children with IDDM 139  
 in medullary thyroid carcinoma 437  
 prandial regulation 412  
 in preterm and term newborns 217  
 in regulation of body composition 329
- Gitelman's syndrome  
 in late adulthood (Letter) 697
- Glucagon  
 in prandial regulation of ghrelin 412
- Glucocorticoid  
 in childhood ALL (Review) 1  
 management of deficiency (Review) 483  
 insufficiency in hyponatraemia (Review) 368
- Glycogen storage disease  
 type 1, ACE-inhibitor therapy 19
- Gonadotrophin releasing hormone agonist  
 treatment of early puberty in girls 185
- Gonadotropins  
 ovarian growth and hyperinsulinaemia 73
- Graves' disease  
 IL-13 and chromosome studies 695  
 optic neuropathy in ophthalmopathy 323  
 psychosocial morbidity of orbitopathy 395  
 relapse, and thyroid blood flow 656  
 susceptibility loci (Letter) 232
- Hashimoto's thyroiditis  
 TPOAb and T-lymphocyte cytokines 191
- Height  
 after treatment of early puberty in girls 185  
 GH therapy in HIV-infected children 259
- HIV infection  
 GH, growth and protein catabolism in children 259
- Homocysteine  
 in subclinical hypothyroidism 582
- HPA (hypothalamo-pituitary-adrenal) axis  
 adaptation in endurance training 530  
 following SARS 197, (Commentary) 363  
 reliability of synacthen test 499  
 salivary cortisol assay 336
- 11 $\beta$ -Hydroxysteroid dehydrogenase  
 adaptation of HPA axis during endurance training 530  
 management of glucocorticoid deficiency (Review) 484  
 type 1, in insulin resistance 442
- 25-Hydroxyvitamin D  
 in primary hyperparathyroidism 506
- Hypercalcaemia  
 milk-alkali syndrome and renal disease 566
- Hypercholesterolaemia  
 in subclinical hypothyroidism 669



- Hypercortisolism
  - following SARS 197, (Commentary) 363
  - post-surgery for Cushing's disease 549
- Hyperglycaemia
  - in hyponatraemia (Review) 367
- Hyperinsulinaemia
  - ovarian growth and gonadotropins 73
- Hypernatraemia
  - acute severe, extrapontine myelinolysis and diabetes insipidus (Letter) 233
- Hyperparathyroidism, primary
  - cardiovascular risk markers 493
  - vitamin D status 506
- Hyperprolactinaemia
  - in chronic renal failure 520
  - clinical follow-up in women 450
- Hypertension
  - in acromegaly and normal population 470
- Hyperthyroidism
  - ambulatory blood pressure monitoring 66
- Hypoadrenalism
  - management of glucocorticoid deficiency (Review) 483
- Hypoandrogenism
  - androgen receptor polymorphism 356
- Hypogonadism
  - androgens, insulin resistance and vascular disease in men (Review) 240, 245
  - long-term somatostatin analogue therapy 342
- Hypokalaemia
  - Gitelman's syndrome in late adulthood (Letter) 697
- Hypoleptinaemia
  - in common variable immunodeficiency syndrome 63
- Hypomagnesaemia
  - Gitelman's syndrome in late adulthood (Letter) 697
- Hyponatraemia
  - pathophysiology, diagnosis and management (Review) 366
- Hypopituitarism
  - genetic factors (Review) 121
  - in hyponatraemia (Review) 368
  - PRO1* mutations in CPHD 10
  - with xanthoma disseminatum (Letter) 119
- Hypothalamo-pituitary axis
  - development (Review) 121
- Hypothyroidism
  - automated thyroid register (Letter) 116
  - in early and late gestation 560
  - evaluation of symptoms and quality of life 616
  - subclinical, in diabetes mellitus type 2 (Letter) 479
  - subclinical, markers for cardiovascular inflammation 582
  - subclinical, and serum lipids 669
  - thyroxine replacement and cardiovascular risk 203
  - TSH receptor gene mutations and resistance 146
- IGFBP-1
  - gender and cardiovascular risk factors 94
- IGF-I
  - erythropoietin administration in athletes 305
  - gender and cardiovascular risk factors 94
  - hypertension in acromegaly and normal population 470
  - low-dose GH in severe GHD 428
  - as predictor of frailty 403
  - in regulation of body composition 329
  - testosterone supplementation in postmenopausal women 32
- Immunodeficiency
  - common variable immunodeficiency syndrome 63
- Infertility
  - androgen receptor polymorphism and androgenicity 356
  - assay for anti-Müllerian hormone 267
- Inflammatory markers
  - C-reactive protein and insulin resistance 350
  - following dermolipectomy 253, (Commentary) 251
  - osteoprotegerin and cardiovascular risk 594
  - as predictors of frailty 403
  - in primary hyperparathyroidism 493
  - in subclinical hypothyroidism 582
- Instruments
  - quality of life and health status in hypothyroidism 616
- Insulin
  - action following dermolipectomy 253, (Commentary) 251
  - ghrelin and galanin in IDDM in children 139
  - ghrelin in preterm and term newborns 217
  - resistance, 11 $\beta$ -hydroxysteroid dehydrogenase type 1 activity 442
  - resistance, androgens and vascular disease in men (Review) 239
  - resistance, in common variable immunodeficiency syndrome 63
  - sensitivity, and low-dose GH in severe GHD 428
  - sensitivity, subclinical inflammation and soleus muscle IMCL 350
- Insulinoma
  - localization (Letter) 480
- Interleukins
  - IL-6, as predictor of frailty 403
  - IL-13, chromosome studies in Graves' disease 695
- Iodine deficiency
  - evaluation of status in children 543
- Lanreotide
  - Autogel®, pharmacokinetic profile in acromegaly 514
  - long-term treatment of acromegaly 342
- Leptin
  - BMD in men 131
  - in common variable immunodeficiency syndrome 63
  - ghrelin in preterm and term newborns 217
- Leukaemia, acute lymphoblastic see ALL
- Lipids
  - effects of testosterone in middle-aged men 280
  - long-term effects of GH therapy 31
  - soleus muscle intramyocellular 350
  - in subclinical hypothyroidism 669

- Macroprolactin
  - in renal replacement therapy 520
- Masculinization
  - differential diagnosis of under-masculinization 375
  - partial androgen insensitivity syndrome 56
- Melatonin
  - phase-shifting effects in older men 298
- Men
  - adipocytokines and BMD 131
  - agomelatine and phase-shifting 298
  - androgens, insulin resistance and vascular disease (Review) 239
  - bone loss in ankylosing spondylitis 467
  - effects of testosterone on sexual function 381, (Commentary) 600
  - elderly, elevated salivary cortisol in type 2 diabetes, 641
  - endocrine regulation of bone turnover (Review) 602
  - infertility, assay for anti-Müllerian hormone 267
  - long-term effects of GH therapy 31
  - long-term somatostatin analogue therapy 342
  - middle-aged, effects of testosterone 280
  - regulation of body composition 329
  - sex hormones, mobility and muscle strength in the elderly 152
- Metabolic syndrome
  - androgens, insulin resistance and vascular disease in men (Review) 239
- Metabolism
  - ghrelin and galanin in type 1 diabetes mellitus 139
- Metformin
  - in ovulation induction in PCOS 630
- Methylprednisolone
  - for optic neuropathy in Graves' ophthalmopathy 323
- Microprolactinoma
  - withdrawal of dopamine agonist therapy 26
- Milk-alkali syndrome
  - renal disease and hypercalcaemia 566
- Mineral homeostasis
  - in childhood ALL (Review) 1
- Mobility
  - sex hormones and gender in the elderly 152
- MRI (magnetic resonance imaging)
  - surveillance imaging for extrapituitary tumours 274
- Multiple endocrine neoplasia (MEN), type 2A
  - prophylactic thyroidectomy in kindreds 635
  - unique phenotype 675
- Muscle strength
  - sex hormones and gender in the elderly 152
- Myelinolysis, extrapontine
  - diabetes insipidus and acute severe hyponatraemia (Letter) 233
- Natriuretic peptide
  - in primary hyperparathyroidism 493
- Nelson's syndrome
  - ACTH secretory process (Letter) 232
- Neonates
  - effects of GH on birth size and early growth 223
  - maternal hypothyroidism in gestation 560
  - preterm and term, and ghrelin 217
- Nephropathy
  - GHD and type 2 diabetes (Letter) 700
  - LMNA 1908C/T polymorphism in type 2 diabetes 317
- Obesity
  - androgens, insulin resistance and vascular disease in men (Review) 242, 245
  - dermolipectomy, insulin action and inflammatory markers 253, (Commentary) 251
  - soleus muscle IMCL 350
- Octreotide therapy
  - in acromegaly 168, 176, 342
- Oestrogens
  - cognition in elderly women 50
- Optic neuropathy
  - treatment in Graves' ophthalmopathy 323
- Orbitopathy, Graves'
  - psychosocial morbidity 395
- Osteopenia
  - in childhood ALL (Review) 1
- Ovarian function
  - assay for anti-Müllerian hormone 267
  - enlargement and hyperinsulinaemia 73
  - ovulation induction 630
  - seladin-1 expression 111
- Ovarian tumours
  - epithelial and granuloma cell 111
- Oxidant-antioxidant status
  - alterations in children with GHD 537
- Parathyroid adenoma
  - weight, in primary hyperparathyroidism 506
- Phase-shifts
  - effects of agomelatine in older men 298
- Pheochromocytoma
  - unique MEN type 2A phenotype 675
- Pituitary adenomas
  - dopamine agonist therapy 39
- Pituitary disease
  - combined pituitary hormone deficiency 10, (Review) 121
  - GHD and antipituitary antibodies 45
- Polycystic ovary syndrome (PCOS)
  - ovulation induction 630
- Pravastatin
  - type 2 diabetes, statins and chylomicron remnant catabolism 649
- Pregnancy
  - hypothyroidism in 560
  - management of glucocorticoid deficiency (Review) 484, 489
- Prolactin
  - in renal replacement therapy 520

- Protein
  - catabolism in HIV-infected children 259
- Pseudohyponatraemia
  - in diagnosis of hyponatraemia (Review) 367
- Psychosocial factors
  - morbidity of Graves' orbitopathy 395
- PTH
  - in regulation of bone turnover in men (Review) 608
- Puberty
  - early, height after treatment 185
  - ghrelin and galanin in type 1 diabetes mellitus 139
- Quality of life
  - AcroQol questionnaire for acromegaly 103
  - in hypothyroidism 616
  - management of glucocorticoid deficiency (Review) 488
  - psychosocial morbidity of Graves' orbitopathy 395
- Radiation therapy
  - external beam, and differentiated thyroid cancer 418
  - GH secretion in acromegaly 294
- Radioactive iodine
  - for differentiated thyroid cancer 418
- Renal disease
  - ACE-inhibitor therapy in GSD1 19
  - diabetic nephropathy and LMNA 1908C/T polymorphism 317
  - hyperprolactinaemia in chronic renal failure 520
  - milk-alkali syndrome and hypercalcaemia 566
  - nephropathy, GHD and type 2 diabetes (Letter) 700
- Resistin
  - BMD in men 131
  - in regulation of body composition 329
- Retinopathy
  - GHD and type 2 diabetes (Letter) 700
- Rosiglitazone
  - long-term, in Cushing's disease (Letter) 118
- SARS (severe acute respiratory syndrome)
  - endocrine sequelae 197, (Commentary) 363
- Seladin-1
  - expression in ovarian tissue and tumours 111
- Septo-optic dysplasia
  - genetic factors (Review) 121
- Sex hormones
  - bone loss in ankylosing spondylitis in men 467
  - mobility and muscle strength in the elderly 152
  - in regulation of bone turnover in men (Review) 605
- Sexual function
  - effects of testosterone in men 381, (Commentary) 600
- SHBG
  - androgens, insulin resistance and vascular disease in men (Review) 242
- Short stature
  - treatment of early puberty in girls 185
- Skeletal morbidity, in childhood ALL (Review) 1
- Soleus muscle
  - IMCL, subclinical inflammation and insulin sensitivity 350
- Somatostatin analogues
  - in acromegaly 168, 176, (Letter) 477, 342, 514
  - pharmacokinetic profile of lanreotide Autogel® 514
- Sonography
  - nonpalpable thyroid nodules 688
- Steroids
  - for optic neuropathy in Graves' ophthalmopathy 323
- Surveillance imaging
  - GH therapy and extrapituitary tumours 274
- Synacthen test
  - audit of reliability 499
- Tai Chi
  - effects on cardiovascular risk factors 662
- Testosterone
  - effects on sexual function in men 381, (Commentary) 600
  - insulin resistance and vascular disease in men (Review) 239
  - measurement in men (Review) 239
  - measurement of normal levels (Letter) 235
  - replacement, insulin resistance and vascular disease in men (Review) 239
  - supplementation in postmenopausal women 32
- Thyroid carcinoma
  - differentiated, in acromegaly 161
  - differentiated, distant metastases and prognostic factors 87
  - differentiated, prognostic factors and effect of therapy 418
  - familial nonmedullary, and T1799A *BRAF* mutation 263
  - medullary, and ghrelin 437
  - medullary, and unique MEN type 2A phenotype 675
  - papillary, *BRAF*<sup>V600E</sup> mutation 461, 588
  - papillary, incidental and non-incidental 577
  - papillary, microcarcinomas 577, 588
- Thyroidectomy
  - prophylactic, in MEN 2A kindreds 635
- Thyroid function
  - ambulatory blood pressure monitoring 66
  - blood flow in Graves' disease 656
  - evaluation of iodine deficiency status 543
  - TPOAb and T-lymphocyte cytokines 191
  - in Williams syndrome 456
- Thyroiditis, Hashimoto's 191
- Thyroid nodules
  - nonpalpable, management 688
- Thyroid register
  - management of hypothyroidism (Letter) 116
- Thyroxine replacement
  - hypothyroidism and cardiovascular risk 203
  - maternal hypothyroidism in gestation 560
- T-Lymphocyte cytokines
  - in Hashimoto's thyroiditis 191

- TNF- $\alpha$ 
  - in diabetic neuropathy 525
- TPO autoantibodies
  - in Hashimoto's thyroiditis 191
- TSH
  - maternal hypothyroidism in gestation 560
  - receptor gene mutations and resistance 146
- Tuberous sclerosis
  - with Cushing's disease (Letter) 693
- Urine
  - analysis of iodine excretion 543
- Vascular growth factors
  - effects of GH status 79
- Vasopressin receptors
  - in familial ACTH-independent macronodular adrenal hyperplasia 624
- Vitamin D
  - in regulation of bone turnover in men (Review) 608
  - status in primary hyperparathyroidism 506
- Williams syndrome
  - thyroid function and morphology 456
- Women
  - clinical follow-up of hyperprolactinaemia 450
  - dermolipectomy, insulin action and inflammatory markers 253, (Commentary) 251
  - hypothyroidism in early and late gestation 560
  - infertility, assay for anti-Müllerian hormone 267
  - long-term somatostatin analogue therapy 342
  - oestrogens and cognition in the elderly 50
  - ovulation induction in PCOS 630
  - postmenopausal, testosterone supplementation 32
  - regulation of body composition 329
  - sex hormones, mobility and muscle strength in the elderly 152
  - subclinical hypothyroidism with diabetes mellitus type 2 (Letter) 479
  - type 2 diabetes, statins and chylomicron remnant catabolism 649
- Xanthoma disseminatum
  - with hypopituitarism (Letter) 119